Article Sidebar

Submitted
Jul 7, 2022
Accepted
Oct 2, 2022
Published
Oct 19, 2022
Download
PDF
Statistic
Read Counter : 276 Download : 320

Main Article Content

Abstract

Schizophrenia is a mental disorder that can affect behavior, emotions and communication. In the agitation phase ithe patient is acompanied by destructive or violent behavior. In these conditions, the patient must immediately calm down to avoid risk. Monotherapy Treatment in acute agitation schizophrenia is recommended than combination therapy. The purpose of this study was to determine the effectiveness of treatment costs and the factors that influence the total cost of schizophrenia patients at the Mental Hospital of West Java Province. This study was observational by cross sectional study design according to the hospital perspective. This method is retrospective data. The subject were inpatients aged 18-65 years with diagnosis of schizophrenia disorder and receiving antipsychotic therapy for at least 1 month. The results showed that average cost-effectiveness ratio (ACER) Rp.288.659/ 1 score PANSS EC with an average decrease score of 9,70. There is a difference in variant data compared because p-value = 0.011<0,05. ICER calculation of A to C = (Rp. 2.800.001–Rp. 2.593.821) / (9.70 - 8.57) = Rp. 182.460. The factors that influence the total cost found that the most significant are administration and room. The conclusion is atypical-atypical monotherapy recommended as a treatment for schizophrenic in agitation acute.

Keywords

Agitation acute Antipsychotics Average Cost Effectiveness Ratio (ACER) Schizophrenia

Article Details

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

How to Cite
Kurnia Utami, I., Barliana, M. I., & Halimah, E. (2022). Cost Analysis of Antipsychotics Schizophrenia of Inpatients in Mental Hospital West Java Province: Analisis Biaya Antipsikotik Pasien Skizofrenia Rawat Inap di Rumah Sakit Jiwa Provinsi Jawa Barat. Jurnal Farmasi Galenika (Galenika Journal of Pharmacy) (e-Journal), 8(2), 143-153. https://doi.org/10.22487/j24428744.2022.v8.i2.15959

References

  1. Cloutier, M., Aigbogun, M. S., Guerin, A., Nitulescu, R., Ramanakumar, A. V., Kamat, S. A., DeLucia, M., Duffy, R., Legacy, S. N., Henderson, C., Francois, C., & Wu, E. (2016). The Economic Burden of Schizophrenia in the United States in 2013. The Journal of Clinical Psychiatry, 77(6), 764–771. https://doi.org/10.4088/JCP.15m10278
  2. Dahlan Sopiyudin, M. (2014). Statistik untuk kedokteran dan kesehatan. Salemba Medika, Jakarta, 84-95.
  3. Dipiro, J.T., Wells, B.G., Schwinghammer, T.L., Dipiro, C.V., 2015, Pharmacotherapy Handbook Ninth Edition-Section 4 Chapter 19, The McGraw-Hill Companies, Inc, United States. (n.d.).
  4. Druais, S., Doutriaux, A., Cognet, M., Godet, A., Lançon, C., Levy, P., Samalin, L., & Guillon, P. (2016). Cost Effectiveness of Paliperidone Long-Acting Injectable Versus Other Antipsychotics for the Maintenance Treatment of Schizophrenia in France. PharmacoEconomics, 34(4), 363–391. https://doi.org/10.1007/s40273-015-0348-x
  5. Escobar, R., San, L., Pérez, V., Olivares, J. M., Polavieja, P., López-Carrero, C., Casillas, M., & Montoya, A. (2008). [Effectiveness results of olanzapine in acute psychotic patients with agitation in the emergency room setting: Results from NATURA study]. Actas Espanolas De Psiquiatria, 36(3), 151–157.
  6. García-Ruiz, A. J., Pérez-Costillas, L., Montesinos, A. C., Alcalde, J., Oyagüez, I., & Casado, M. A. (2012). Cost-effectiveness analysis of antipsychotics in reducing schizophrenia relapses. Health Economics Review, 2(1), 8. https://doi.org/10.1186/2191-1991-2-8
  7. Gründer, G., Heinze, M., Cordes, J., Mühlbauer, B., Juckel, G., Schulz, C., Rüther, E., Timm, J., & NeSSy Study Group. (2016). Effects of first-generation antipsychotics versus second-generation antipsychotics on quality of life in schizophrenia: A double-blind, randomised study. The Lancet. Psychiatry, 3(8), 717–729. https://doi.org/10.1016/S2215-0366(16)00085-7
  8. Ministry of health RI. Basic health research, 2018. Jakarta: Health ministry of research and development of health RI. (n.d.) http://www.depkes.go.id/resources/download/infoterkini/material_rakorpop_2018/Hasil%20Riskesdas%202018.pdf-Accesed August 2019.
  9. Montoya, A., Valladares, A., Lizán, L., San, L., Escobar, R., & Paz, S. (2011). Validation of the Excited Component of the Positive and Negative Syndrome Scale (PANSS-EC) in a naturalistic sample of 278 patients with acute psychosis and agitation in a psychiatric emergency room. Health and Quality of Life Outcomes, 9(1), 18. https://doi.org/10.1186/1477-7525-9-18
  10. Park, T., & Kuntz, K. M. (2014). Cost-Effectiveness of Second-Generation Antipsychotics for the Treatment of Schizophrenia. Value in Health, 17(4), 310–319. https://doi.org/10.1016/j.jval.2014.02.008
  11. Putri, A. W., Wibhawa, B., & Gutama, A. S. (2015). KESEHATAN MENTAL MASYARAKAT INDONESIA (PENGETAHUAN, DAN KETERBUKAAN MASYARAKAT TERHADAP GANGGUAN KESEHATAN MENTAL). Prosiding Penelitian dan Pengabdian kepada Masyarakat, 2(2). https://doi.org/10.24198/jppm.v2i2.13535
  12. Schwartz, T. (2018). Fine Tuning the Use of Second Generation Antipsychotics. JOURNAL OF MENTAL HEALTH AND CLINICAL PSYCHOLOGY, 2(5), 22–39. https://doi.org/10.29245/2578-2959/2018/5.1138
  13. Seeman, P. (2002). Atypical Antipsychotics: Mechanism of Action. The Canadian Journal of Psychiatry, 47(1), 29–40. https://doi.org/10.1177/070674370204700106
  14. Suzuki, H., Gen, K., & Takahashi, Y. (2013). A naturalistic comparison of the efficacy and safety of intramuscular olanzapine and intramuscular haloperidol in agitated elderly patients with schizophrenia. Therapeutic Advances in Psychopharmacology, 3(6), 314–321. https://doi.org/10.1177/2045125313496113
  15. Tesfaye, S., Debencho, N., Kisi, T., & Tareke, M. (2016). Prevalence of Antipsychotic Polypharmacy and Associated Factors among Outpatients with Schizophrenia Attending Amanuel Mental Specialized Hospital, Addis Ababa, Ethiopia. Psychiatry Journal, 2016, 1–6. https://doi.org/10.1155/2016/6191074
  16. Vos, T., Abajobir, A. A., Abate, K. H., Abbafati, C., Abbas, K. M., Abd-Allah, F., Abdulkader, R. S., Abdulle, A. M., Abebo, T. A., Abera, S. F., Aboyans, V., Abu-Raddad, L. J., Ackerman, I. N., Adamu, A. A., Adetokunboh, O., Afarideh, M., Afshin, A., Agarwal, S. K., Aggarwal, R., … Murray, C. J. L. (2017). Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990–2016: A systematic analysis for the Global Burden of Disease Study 2016. The Lancet, 390(10100), 1211–1259. https://doi.org/10.1016/S0140-6736(17)32154-2
  17. Yeh, Y., Yu, X., Zhang, C., Hao, W., Du, F., Liu, D., Yang, L., & Gao, X. (2018). Cost Analysis Model for the Treatment of Acute Agitation Among Patients with Schizophrenia in China. Value in Health, 21, S184. https://doi.org/10.1016/j.jval.2018.04.1256
  18. Zhu, B., Ascher-Svanum, H., Faries, D. E., Peng, X., Salkever, D., & Slade, E. P. (2008). Costs of treating patients with schizophrenia who have illness-related crisis events. BMC Psychiatry, 8(1), 72. https://doi.org/10.1186/1471-244X-8-72

DB Error: Unknown column 'Array' in 'where clause'